Chemotherapeutic regimens, such as cyclophosphamide+doxorubicin+5FU (CAF) or cyclophosphamide+methotrexate+5FU (CMF), are sometimes used in combination with endocrine or radiotherapy as a standard first line of treatment for recurrent or metastatic breast cancer. However, many cases are, or become, refractory to these treatments.
Twenty-one women with recurrent or metastatic breast cancer who previously underwent treatment were administered our original regimen of combination chemotherapy, MFL-P: Day 1, bolus methotrexate (MTX) 50 mg/body (median dose, 33 mg/m2; range, 29–35 mg/m2) and 4 hours later 5-fluorouracil (5FU) 750 mg/body/h (median dose, 497 mg/m2/h; range, 441–528 mg/m2/h); Days 2–3, bolus leucovorin (LV) 15 mg/body every 8 h×3; Days 2–5, 72 hours continuous 5FU 750 mg/body/24 h; Day 6, cisplatin (CDDP) 50 mg/body/h (median dose, 33 mg/m2/h; range, 29–35 mg/m2/h) with sufficient hydration. The subjects ranged in age from 26 to 63 years (mean age, 51.3 years).
One complete and 9 partial responses were achieved among the 20 patients (response rate, 50%). In 1 patient, diffuse liver metastasis was not measurable. Among various metastatic sites, a higher response rate was observed especially for soft tissue lesions (skin, chest wall and lymph nodes; 9 responders among 11 lesions). On the other hand, in visceral or skeletal metastases, the response rate was poor. The adverse effects were tolerable in all patients, except for common low-grade stomatitis or anorexia.
MFL-P is useful as a second or third line of therapy for patients with refractory, recurrent or metastatic breast cancer with soft tissues lesions.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
MTX + 5FU + LV + CDDP
Cyclophosphamide + ADR + 5FU
Cyclophosphamide + MTX + 5FU
Bruckner HW, Cohen J: MTX/5-FU trials in gastrointestinal and other cancer.Semin Oncol 10 (suppl 2):32–39, 1983.
Gohdmann JJ, Macdonald JS: Chemotherapy of gastric cancer.Cancer Invest 7:39–52, 1989.
Kan N, Okino T, Inoue K,et al: Evaluation of outpatient cisplatin for patients with advanced or recurrent gastric cancer; Combination with immunotherapy or other anti-cancer agents.Kiso to Rinsyou 28:833–841, 1994(in Japanese with English abstract).
Japanese Society for Cancer Therapy: General Rules for Reporting on Clinical Oncology, 1st ed, Kanehara, Tokyo, ppl-101, 1991.
Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 12th ed, Kanehara, Tokyo, ppl-68, 1996.
Scanlon KJ, Newman EM, Lu Y,et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.Proc Natl Acad Sci USA 83:8923–8925, 1986.
Nashimoto A, Sasaki J, Akai S,et al: Ambulatory combination chemotherapy with cisplatin and 5-fluorouracil for advanced gastric cancer patients.J Jpn Soc Cancer Ther 27:654–664, 1992.
Creagan ET, Richardson RL, Kavach JS: Pilot study of a continuous five-day intravenous infusion of etopo-side concomitant with cisplatin in selected patients with advanced cancer.J Clin Oncol 6:1197–1201, 1988.
Lokich JJ, Ahlgren JD, Cantrell J,et al: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma; A Mid-Atlantic Oncology Program study.Cancer 67:14–19, 1991.
Suga S, Kimura K, Nagai H,et al: An evaluation of gastric cancers given UFT/CDDP chemotherapy.Gan no Rinsyou 37:929–939, 1991(in Japanese with English abstract).
Klaassen U, Wilke H, Weyhofen R,et al: Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.Anti-Cancer Drugs 9:203–207, 1998.
Sasaki T: Sequential methotrexate and 5-fluorouracil.Jpn J Cancer Chemother 23:1907–1910, 1996.
Oura S, Sakura T, Yoshimura G,et al: Result of biochemical modulation therapy of 5-FU with low dose cisplatin for anthracycline resistant breast carcinoma.J Jpn Soc Cancer Ther 31:957–964, 1996.
Alonso V, Santander C, Florian J,et al: Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer.Tumori 82:61–64, 1996.
Haaz MC, Fischel JL, Forment P,et al: Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.Cancer Chemother Pharmacol 38:52–58, 1996.
Okino T, Kan N, Satoh K,et al: Therapeutic effect of sequential chemotherapy using methotrexate, 5-FU, leucovorin and cisplatin (MFLP) against advanced and/or recurrent gastric cancer. In: Siewert JR, Roder JD eds, Progress in Gastric Cancer Research 1997, Monduzzi Editore SpA, Bologna, ppl819–1823, 1997.
Platesi G, Gianni L, Manzotti C,et al: Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice.Cancer Chemother Pharmacol 21:237–240, 1988.
Kuroki M, Nakano S, Mitsugi K,et al:In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line.Cancer Chemother Pharmacol 29:273–276, 1992.
Furukawa S, Yoshida T, Tukuda M,et al: Experimental study on combination chemotherapy with platinum compounds and 5-fluorouracil.Jpn J Cancer Chemother 16(part-I):419–422, 1989.
Esaki T, Nakano S, Matsumoto N,et al: Schedule-dependent reversion by 5-fluorouracil in a newly established cisplatin-resistent HST-1 human squamous carcinoma cell line.Int J Cancer 65:479–484, 1996.
Nakano S, Niho Y: 5-Fluorouracil and cisplatin sequential chemotherapy; Mechanism of action and clinical application in advanced, unresectable non-small cell lung cancer.Intern Med 34:288–291, 1995.
Bruckner HW, Chesser MR, Wong H,et al: Folate biochemical modulation regimen for the treatment of gastric cancer.J Clin Gastroenterol 13:384–389, 1991.
About this article
Cite this article
Kan, N., Honda, G. MFL-P chemotherapy for pretreated metastatic Breast Cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP. Breast Cancer 6, 187–191 (1999). https://doi.org/10.1007/BF02967166